Which has stronger valuation and earnings, TLX or LBRX?

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 4.04 -$7.12M N/A N/A LB Pharmaceuticals N/A N/A -$25.20M -$1.73 N/A

Is TLX or LBRX more profitable?

Company Net Margins Return on Equity Return on Assets Telix Pharmaceuticals N/A N/A N/A LB Pharmaceuticals N/A N/A N/A

Does the media favor TLX or LBRX?

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 2 articles in the media. Telix Pharmaceuticals' average media sentiment score of 1.50 beat LB Pharmaceuticals' score of 0.93 indicating that Telix Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is DNLI or LBRX more profitable?

LB Pharmaceuticals' return on equity of 0.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% LB Pharmaceuticals N/A N/A N/A

Does the media favor DNLI or LBRX?

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. LB Pharmaceuticals' average media sentiment score of 0.93 beat Denali Therapeutics' score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LBRX or BEAM?

In the previous week, Beam Therapeutics had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for LB Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.04 beat LB Pharmaceuticals' score of 0.93 indicating that Beam Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beam Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TNGX or LBRX?

In the previous week, Tango Therapeutics had 21 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 23 mentions for Tango Therapeutics and 2 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.93 beat Tango Therapeutics' score of 0.19 indicating that LB Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 3 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 6 Very Negative mention(s) Neutral LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RCUS or LBRX?

In the previous week, Arcus Biosciences had 19 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 21 mentions for Arcus Biosciences and 2 mentions for LB Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.99 beat LB Pharmaceuticals' score of 0.93 indicating that Arcus Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcus Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive LB Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

LB Pharmaceuticals (LBRX) Competitors

$28.42 -0.12 (-0.42%)

Closing price 04:00 PM Eastern

Extended Trading

$28.42 0.00 (0.00%)

As of 04:24 PM Eastern

Compare

LBRX vs. TLX, DNLI, BEAM, TNGX, and RCUS

Should you buy LB Pharmaceuticals stock or one of its competitors? MarketBeat compares LB Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with LB Pharmaceuticals include Telix Pharmaceuticals (TLX), Denali Therapeutics (DNLI), Beam Therapeutics (BEAM), Tango Therapeutics (TNGX), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Telix Pharmaceuticals presently has a consensus target price of $21.13, indicating a potential upside of 120.97%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 35.12%. Given Telix Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Telix Pharmaceuticals is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Telix Pharmaceuticals has higher revenue and earnings than LB Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	4.04	-$7.12M	N/A	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

In the previous week, Telix Pharmaceuticals and Telix Pharmaceuticals both had 2 articles in the media. Telix Pharmaceuticals' average media sentiment score of 1.50 beat LB Pharmaceuticals' score of 0.93 indicating that Telix Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
LB Pharmaceuticals	N/A	N/A	N/A

Summary

Telix Pharmaceuticals beats LB Pharmaceuticals on 6 of the 6 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

LB Pharmaceuticals has lower revenue, but higher earnings than Denali Therapeutics. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	10.40	-$512.54M	-$2.88	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

92.9% of Denali Therapeutics shares are held by institutional investors. 12.5% of Denali Therapeutics shares are held by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Denali Therapeutics and Denali Therapeutics both had 2 articles in the media. LB Pharmaceuticals' average media sentiment score of 0.93 beat Denali Therapeutics' score of 0.62 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals' return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
LB Pharmaceuticals	N/A	N/A	N/A

Denali Therapeutics presently has a consensus target price of $34.25, indicating a potential upside of 58.13%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 35.12%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Denali Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Denali Therapeutics beats LB Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Beam Therapeutics?

LB Pharmaceuticals (NASDAQ:LBRX) and Beam Therapeutics (NASDAQ:BEAM) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations and earnings.

LB Pharmaceuticals presently has a consensus price target of $38.40, indicating a potential upside of 35.12%. Beam Therapeutics has a consensus price target of $46.83, indicating a potential upside of 61.33%. Given Beam Therapeutics' higher probable upside, analysts plainly believe Beam Therapeutics is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71

In the previous week, Beam Therapeutics had 4 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for LB Pharmaceuticals. Beam Therapeutics' average media sentiment score of 1.04 beat LB Pharmaceuticals' score of 0.93 indicating that Beam Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A
Beam Therapeutics	$139.74M	21.37	-$79.99M	-$0.68	N/A

LB Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. LB Pharmaceuticals' return on equity of 0.00% beat Beam Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LB Pharmaceuticals	N/A	N/A	N/A
Beam Therapeutics	-39.66%	-29.00%	-22.61%

99.7% of Beam Therapeutics shares are held by institutional investors. 5.8% of LB Pharmaceuticals shares are held by insiders. Comparatively, 3.8% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

LB Pharmaceuticals and Beam Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

In the previous week, Tango Therapeutics had 21 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 23 mentions for Tango Therapeutics and 2 mentions for LB Pharmaceuticals. LB Pharmaceuticals' average media sentiment score of 0.93 beat Tango Therapeutics' score of 0.19 indicating that LB Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	6 Very Negative mention(s)	Neutral
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals has a net margin of 0.00% compared to Tango Therapeutics' net margin of -151.15%. LB Pharmaceuticals' return on equity of 0.00% beat Tango Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	-151.15%	-41.54%	-33.44%
LB Pharmaceuticals	N/A	N/A	N/A

79.0% of Tango Therapeutics shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

LB Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than LB Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$56.99M	78.53	-$101.59M	-$0.83	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

Tango Therapeutics currently has a consensus target price of $38.42, suggesting a potential upside of 24.17%. LB Pharmaceuticals has a consensus target price of $38.40, suggesting a potential upside of 35.12%. Given LB Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe LB Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

LB Pharmaceuticals beats Tango Therapeutics on 9 of the 15 factors compared between the two stocks.

How does LB Pharmaceuticals compare to Arcus Biosciences?

Arcus Biosciences (NYSE:RCUS) and LB Pharmaceuticals (NASDAQ:LBRX) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

LB Pharmaceuticals has lower revenue, but higher earnings than Arcus Biosciences. LB Pharmaceuticals is trading at a lower price-to-earnings ratio than Arcus Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcus Biosciences	$247M	12.14	-$353M	-$3.18	N/A
LB Pharmaceuticals	N/A	N/A	-$25.20M	-$1.73	N/A

92.9% of Arcus Biosciences shares are owned by institutional investors. 9.6% of Arcus Biosciences shares are owned by company insiders. Comparatively, 5.8% of LB Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Arcus Biosciences had 19 more articles in the media than LB Pharmaceuticals. MarketBeat recorded 21 mentions for Arcus Biosciences and 2 mentions for LB Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.99 beat LB Pharmaceuticals' score of 0.93 indicating that Arcus Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcus Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
LB Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

LB Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. LB Pharmaceuticals' return on equity of 0.00% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcus Biosciences	-156.36%	-68.97%	-35.27%
LB Pharmaceuticals	N/A	N/A	N/A

Arcus Biosciences presently has a consensus target price of $35.10, indicating a potential upside of 47.17%. LB Pharmaceuticals has a consensus target price of $38.40, indicating a potential upside of 35.12%. Given Arcus Biosciences' higher probable upside, analysts plainly believe Arcus Biosciences is more favorable than LB Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58
LB Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Arcus Biosciences beats LB Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

Get LB Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LBRX vs. The Competition

Export

Metric	LB Pharmaceuticals	Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$815.09M	$2.95B	$4.29B	$11.97B
Dividend Yield	N/A	15.24%	9.53%	5.57%
P/E Ratio	-16.43	13.63	22.16	24.47
Price / Sales	N/A	3,070.73	122.55	122.57
Price / Cash	N/A	26.46	40.76	54.62
Price / Book	2.39	4.38	27.43	6.81
Net Income	-$25.20M	-$40.09M	$118.48M	$337.76M
7 Day Performance	-0.39%	0.85%	0.61%	2.19%
1 Month Performance	-8.71%	0.05%	0.59%	3.23%
1 Year Performance	N/A	15.63%	12.90%	27.91%

LB Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LBRX LB Pharmaceuticals	2.1215 of 5 stars	$28.42 -0.4%	$38.40 +35.1%	N/A	$815.09M	N/A	N/A	16
TLX Telix Pharmaceuticals	4.4878 of 5 stars	$9.22 -0.9%	$21.13 +129.1%	-44.5%	$3.16B	$803.79M	N/A	1,184
DNLI Denali Therapeutics	2.9987 of 5 stars	$19.54 +0.1%	$34.25 +75.3%	+38.4%	$3.10B	$330.53M	N/A	430
BEAM Beam Therapeutics	3.2655 of 5 stars	$29.78 +1.3%	$46.83 +57.3%	+64.4%	$3.02B	$139.74M	N/A	510	Positive News
TNGX Tango Therapeutics	2.4379 of 5 stars	$30.93 +53.0%	$34.17 +10.5%	+529.1%	$2.92B	$62.38M	N/A	90	Analyst Forecast Analyst Revision High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LBRX) was last updated on 6/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does LB Pharmaceuticals compare to Denali Therapeutics?

Summary

How does LB Pharmaceuticals compare to Beam Therapeutics?

Summary

How does LB Pharmaceuticals compare to Tango Therapeutics?

Summary

How does LB Pharmaceuticals compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

LB Pharmaceuticals (LBRX) Competitors

LBRX vs. TLX, DNLI, BEAM, TNGX, and RCUS

How does LB Pharmaceuticals compare to Telix Pharmaceuticals?

Do analysts rate TLX or LBRX?

Which has stronger valuation and earnings, TLX or LBRX?

Does the media favor TLX or LBRX?

Is TLX or LBRX more profitable?

Summary

How does LB Pharmaceuticals compare to Denali Therapeutics?

Which has preferable valuation and earnings, DNLI or LBRX?

Do insiders and institutionals believe in DNLI or LBRX?

Does the media favor DNLI or LBRX?

Is DNLI or LBRX more profitable?

Do analysts prefer DNLI or LBRX?

Summary

How does LB Pharmaceuticals compare to Beam Therapeutics?

Do analysts prefer LBRX or BEAM?

Does the media favor LBRX or BEAM?

Which has stronger earnings & valuation, LBRX or BEAM?

Is LBRX or BEAM more profitable?

Do institutionals & insiders believe in LBRX or BEAM?

Summary

How does LB Pharmaceuticals compare to Tango Therapeutics?

Does the media refer more to TNGX or LBRX?

Is TNGX or LBRX more profitable?

Do insiders & institutionals have more ownership in TNGX or LBRX?

Which has stronger valuation & earnings, TNGX or LBRX?

Do analysts recommend TNGX or LBRX?

Summary

How does LB Pharmaceuticals compare to Arcus Biosciences?

Which has better valuation and earnings, RCUS or LBRX?

Do institutionals and insiders believe in RCUS or LBRX?

Does the media prefer RCUS or LBRX?

Is RCUS or LBRX more profitable?

Do analysts recommend RCUS or LBRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LBRX vs. The Competition

LB Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools